EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lung Transplant Immunomodulation with Genetically Engineered Mesenchymal Stromal Cells—Therapeutic Window for Interleukin-10

Antti I Nykänen iD, Andrea Mariscal iD, Allen Duong, Aadil Ali, Akihiro Takahagi iD, Xiaohui Bai, Guan Zehong, Betty Joe, Mamoru Takahashi, Manyin Chen, Hemant Gokhale iD, Hongchao Shan iD und 10 weitere

Cells · 17.05.2024 · 13 (10) · 859

DOI: 10.3390/cells13100859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 17.05.2024. Verfasst von Antti I Nykänen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada. Hauptthemen laut MEDLINE: Lung Transplantation, Interleukin-10, Mesenchymal Stem Cells, Immunomodulation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Sigrid Jusélius Foundation, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung transplantation results are compromised by ischemia–reperfusion injury and alloimmune responses. Ex vivo lung perfusion (EVLP) is used to assess marginal donor lungs before transplantation but is also an excellent platform to apply novel therapeutics. We investigated donor lung immunomodulation using genetically engineered mesenchymal stromal cells with augmented production of human anti-inflammatory hIL-10 (MSCsIL-10). Pig lungs were placed on EVLP for 6 h and randomized to control (n = 7), intravascular delivery of 20 × 106 (n = 5, low dose) or 40 × 106 human MSCs IL-10 (n = 6, high dose). Subsequently, single-lung transplantation was performed, and recipient pigs were monitored for 3 days. hIL-10 secretion was measured during EVLP and after transplantation, and immunological effects were assessed by cytokine profile, T and myeloid cell characterization and mixed lymphocyte reaction. MSCIL-10 therapy rapidly increased hIL-10 during EVLP and resulted in transient hIL-10 elevation after lung transplantation. MSCIL-10 delivery did not affect lung function but was associated with dose-related immunomodulatory effects, with the low dose resulting in a beneficial decrease in apoptosis and lower macrophage activation, but the high MSCIL-10 dose resulting in inflammation and cytotoxic CD8+ T cell activation. MSCIL-10 therapy during EVLP results in a rapid and transient perioperative hIL-10 increase and has a therapeutic window for its immunomodulatory effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationInterleukin-10Mesenchymal Stem CellsImmunomodulationMesenchymal Stem Cell TransplantationAnimalsSwineHumansGenetic EngineeringLung

Stichwörter der Autor:innen

cell therapyex vivo lung perfusiongene therapyinterleukin-10lung transplantation

Substanzen

Interleukin-10

Autor:innen und Institutionen

  • Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Division of Thoracic Surgery, Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5T 1P5, Canada.
  • Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, ON M5G 2N2, Canada.
  • Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
  • Tissue Regeneration Therapeutics, Toronto, ON M5G 1N8, Canada.

ORCID-Profile: Antti I Nykänen, Andrea Mariscal, Akihiro Takahagi, Hemant Gokhale, Hongchao Shan, Stephen Juvet, Mingyao Liu

Förderung

  • CIHR
  • Sigrid Jusélius Foundation
  • Canadian Institutes of Health Research

Zitieren

APA

Nykänen, A. I., Mariscal, A., Duong, A., Ali, A., Takahagi, A., Bai, X., Zehong, G., Joe, B., Takahashi, M., Chen, M., Gokhale, H., Shan, H., Hwang, D. M., Estrada, C., Yeung, J., Waddell, T., Martinu, T., Juvet, S., Cypel, M., …, & Keshavjee, S. (2024). Lung Transplant Immunomodulation with Genetically Engineered Mesenchymal Stromal Cells—Therapeutic Window for Interleukin-10. Cells, 13(10), 859. https://doi.org/10.3390/cells13100859

Vancouver

Nykänen AI, Mariscal A, Duong A, Ali A, Takahagi A, Bai X, et al. Lung Transplant Immunomodulation with Genetically Engineered Mesenchymal Stromal Cells—Therapeutic Window for Interleukin-10. Cells. 2024;13(10):859. doi:10.3390/cells13100859

BibTeX
@article{Nyknen2024,
  author = {Nykänen, Antti I and Mariscal, Andrea and Duong, Allen and Ali, Aadil and Takahagi, Akihiro and Bai, Xiaohui and Zehong, Guan and Joe, Betty and Takahashi, Mamoru and Chen, Manyin and Gokhale, Hemant and Shan, Hongchao and Hwang, David M and Estrada, Catalina and Yeung, Jonathan and Waddell, Tom and Martinu, Tereza and Juvet, Stephen and Cypel, Marcelo and Liu, Mingyao and Davies, John E and Keshavjee, Shaf},
  title = {Lung Transplant Immunomodulation with Genetically Engineered Mesenchymal Stromal Cells—Therapeutic Window for Interleukin-10},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {859},
  doi = {10.3390/cells13100859}
}
Kostenlos starten →